CHO-plus

Executive Summary

CHO-plus is a private, early-stage biotechnology company based in Cambridge, MA, focused on addressing a critical bottleneck in biologics and cell therapy manufacturing: protein yield. By leveraging proprietary genetic engineering of Chinese Hamster Ovary (CHO) cells, the company aims to significantly increase the output per bioreactor, reducing the cost and time needed to produce therapeutic proteins, antibodies, and cell therapies. This technology targets the growing demand for high-volume, cost-effective biologics production, particularly as personalized cell therapies scale up.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Announcement70% success
• Q4 2026Proof-of-Concept Data from Pilot Cell Lines60% success
• Q1 2027Strategic Partnership with a Large CDMO50% success